Forskolin Shows Dual Mechanism Against Aggressive KMT2A-Rearranged Acute Myeloid Leukemia
核心洞察
Forskolin, a natural plant compound, demonstrates dual anti-leukemic activity by directly slowing cancer cell growth and enhancing chemotherapy effectiveness in KMT2A-rearranged AML (搜索).
The compound activates Protein Phosphatase 2A (搜索) and reduces cancer-linked gene activity while also inhibiting P-glycoprotein 1 (搜索) to improve daunorubicin retention in leukemia (搜索) cells.
Research from the University of Surrey suggests combining forskolin with daunorubicin could enable lower chemotherapy doses and reduce severe side effects.
Researchers at the University of Surrey have identified a promising dual mechanism by which forskolin, a natural plant-derived compound, could significantly enhance treatment outcomes for KMT2A-rearranged Acute Myeloid Leukemia (搜索) (KMT2A-r AML (搜索)), one of the most aggressive forms of leukemia (搜索). The findings, published in the British Journal of Pharmacology, reveal that forskolin not only directly inhibits leukemia cell growth but also dramatically improves the effectiveness of standard chemotherapy drugs.
Dual Anti-Leukemic Mechanisms Discovered
The Surrey research team discovered that forskolin operates through two distinct pathways to combat KMT2A-r AML (搜索). First, the compound activates Protein Phosphatase 2A (搜索) (PP2A (搜索)) and reduces the activity of several cancer-linked genes, including MYC (搜索), HOXA9 (搜索), and HOXA10 (搜索), directly slowing leukemia (搜索) cell proliferation.
The second mechanism represents a particularly significant breakthrough. Forskolin dramatically enhanced the sensitivity of KMT2A-r AML (搜索) cells to daunorubicin, a standard chemotherapy drug. Notably, this enhancement occurs independently of PP2A (搜索) activation and instead involves the inhibition of P-glycoprotein 1 (搜索), a protein that cancer cells use to expel chemotherapy drugs from their interior.
Enhanced Chemotherapy Retention and Efficacy
By limiting P-glycoprotein 1 (搜索)'s function, forskolin ensures that more daunorubicin remains inside leukemia (搜索) cells, thereby intensifying the drug's therapeutic effects. This mechanism could potentially allow for lower chemotherapy doses while maintaining or improving treatment efficacy.
"Our findings have highlighted an exciting dual mechanism of action for forskolin," said Dr. Maria Teresa Esposito, Senior Lecturer in Biochemistry at the University of Surrey. "Not only does it have direct anti-leukemic effects, but it also acts as a powerful enhancer to conventional chemotherapy. Combining forskolin with daunorubicin could lead to a more effective treatment strategy, potentially allowing for lower doses of chemotherapy and reducing the severe side effects often associated with AML (搜索) treatments."
Clinical Implications for Aggressive Leukemia
The research addresses a critical unmet need in treating KMT2A-r AML (搜索), which represents one of the most challenging forms of acute myeloid leukemia (搜索). Dr. Simon Ridley, Director of Research and Advocacy at Leukemia UK (搜索), emphasized the significance of these findings for patient outcomes.
"AML (搜索) is one of the most aggressive and deadly cancer types, and this study not only deepens our understanding of KMT2A-rearranged AML but also opens the door to kinder, more effective treatments," Ridley stated. "Work like this is essential if we are to achieve our goal of doubling the five-year survival rate for AML within the next decade."
Multi-Institutional Collaboration
The research was supported by Leukaemia UK and represents a collaborative effort involving multiple prestigious institutions, including the University of Roehampton (搜索), Barts Cancer Institute-Queen Mary University of London, Great Ormond Street Institute (搜索) of Child Health London-UCL, and the Genomic Regulation, CRG Barcelona in Spain. This broad collaboration underscores the significance and potential impact of the findings in advancing treatment strategies for this formidable oncological challenge.